On September 12, 2022 Nimbus Therapeutics, a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, reported the closing of a $125 million private financing (Press release, Nimbus Therapeutics, SEP 12, 2022, View Source [SID1234619397]). The round involves participation from new investors Bain Capital Life Sciences and SV Health Investors, along with existing investors including Access Biotechnology, Atlas Venture, BVF Partners L.P., Bill Gates, Lightstone Ventures, Pfizer Ventures, RA Capital Management and SR One.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The strong support from investors in this financing validates the promise and differentiation of Nimbus’ current portfolio of clinical and preclinical programs, and the success of our productive drug discovery engine," said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. "I’m pleased to welcome SV Health Investors and Bain Capital Life Sciences to Nimbus’ investor syndicate at this very exciting time in our history, and look forward to generating and sharing critical data for our medicines in development in the near term."
The financing will support the completion of the ongoing Phase 2b clinical trials of NDI-034858, Nimbus’ oral allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis and active psoriatic arthritis, the initiation of psoriasis Phase 3 trials, as well as the initiation of additional Phase 2b clinical trials of NDI-034858 in other autoimmune indications, including inflammatory bowel disease (IBD) and lupus.
The financing also will support the ongoing Phase 1/2 clinical trials of NDI-101150, Nimbus’ hematopoietic progenitor kinase 1 (HPK1) inhibitor, in patients with solid tumors, as well as preclinical development of programs targeting Casitas B-lineage lymphoma b (Cbl-b) and Werner syndrome helicase (WRN), along with ongoing discovery efforts across a range of targets.
"We’re proud to lead this financing round to advance Nimbus’ exciting pipeline of clinical and preclinical candidates," said Nikola Trbovic, Ph.D., Partner at SV Health Investors. "Nimbus has a remarkable track record of success in discovering and developing differentiated small molecule therapies to address substantial unmet medical needs, and we’re excited to support their current portfolio of programs."
In addition to this financing, Nimbus has recently appointed Gorjan Hrustanovic, Ph.D., Managing Director of BVF Partners, L.P., to its Board of Directors. Dr. Hrustanovic serves on a number of other public and private biotech boards, and trained in cancer biology and translational medicine at the University of California, San Francisco.